While targeting this axis represents a potential therapeutic strategy to overcome cancer progression and treatment resistance, further research is needed to fully understand the complex mechanisms underlying CD44-mediated pro-tumorigenic signalling and whether targeting the hyaluronan/CD44 axis ultimately improves patient outcomes in cancer therapy. Here, CD44 is linked to cancer.